The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The company shows very weak stock market performance, in line with its fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Allurion Technologies Inc's Score
Industry at a Glance
Industry Ranking
190 / 485
Overall Ranking
299 / 4616
Industry
Software & IT Services
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analyst Rating
Based on
3
analysts
Buy
Current Rating
5.833
Target Price
+222.28%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Allurion Technologies Inc Highlights
StrengthsRisks
Allurion Technologies, Inc. offers Allurion Program, which is a weight loss platform that combines the Allurion Gastric Balloon for weight loss. The Company offers Allurion Virtual Care Suite, including the Allurion Mobile App for consumers, Allurion Insights for health care providers featuring the Iris AI Platform and health tracker devices. Its health tracker devices include Allurion Connected Scale and Allurion Health Tracker. Allurion Connected Scale offers a complete weight tracking experience, allowing users to monitor their weight, body mass index (BMI) and body composition. Allurion Health Tracker tracks steps, exercise and sleep. Allurion Virtual Care Suite is available to providers separately from the Allurion Program to help customize, monitor and manage weight-loss therapy for patients regardless of their treatment plan, which includes gastric balloon, surgical and medical or nutritional. Its Allurion Programme is offered in six months, 12 months and 12-18 months program.
Growing
The company is in a growing phase, with the latest annual income totaling USD 32.11M.
Overvalued
The company’s latest PE is -0.01, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 3.18M shares, decreasing 11.77% quarter-over-quarter.
Allurion Technologies, Inc. offers Allurion Program, which is a weight loss platform that combines the Allurion Gastric Balloon for weight loss. The Company offers Allurion Virtual Care Suite, including the Allurion Mobile App for consumers, Allurion Insights for health care providers featuring the Iris AI Platform and health tracker devices. Its health tracker devices include Allurion Connected Scale and Allurion Health Tracker. Allurion Connected Scale offers a complete weight tracking experience, allowing users to monitor their weight, body mass index (BMI) and body composition. Allurion Health Tracker tracks steps, exercise and sleep. Allurion Virtual Care Suite is available to providers separately from the Allurion Program to help customize, monitor and manage weight-loss therapy for patients regardless of their treatment plan, which includes gastric balloon, surgical and medical or nutritional. Its Allurion Programme is offered in six months, 12 months and 12-18 months program.